Dermawound Wound Care Venous Stasis Ointment
NDC 57554-120

View dosage, usage, ingredients, routes, and UNII mappings.

Product Information

Dermawound Wound Care Venous Stasis (benzocaine hydrochloride) is a OTC MONOGRAPH DRUG-approved product labeled by Progressive Doctors, Llc. This medication is typically used as a allergens [cs]. It is supplied as a ointment for topical administration. This product entry covers the primary NDC 57554-120 and its associated package configuration. This profile includes active and inactive ingredient UNII references and FDA labeling data.

Primary Identification

NDC Product Code:
57554-120
Proprietary Name:
Dermawound Wound Care Venous Stasis
Non-Proprietary Name: [1]
Benzocaine Hydrochloride
Substance Name: [2]
Benzocaine
NDC Directory Status:
Human Otc Drug
Product Type: [3]
ACTIVE PRODUCT INCLUDED in the NDC Directory
Code Navigator:

Clinical Specifications

Dosage Form:
Ointment - A semisolid3 dosage form, usually containing <20% water and volatiles5 and >50% hydrocarbons, waxes, or polyols as the vehicle. This dosage form is generally for external application to the skin or mucous membranes.
Administration Route(s): [4]
Topical - Administration to a particular spot on the outer surface of the body. The E2B term TRANSMAMMARY is a subset of the term TOPICAL.

Labeler & Regulatory Data

Labeler Code:
57554
FDA Application Number: [6]
M017
Marketing Category: [8]
OTC MONOGRAPH DRUG

Marketing Timeline

Start Marketing Date: [9]
02-01-2014
Listing Expiration Date: [11]
12-31-2026
Exclude Flag: [12]
N

Code Structure Chart

Product Details

What is NDC 57554-120?

The NDC code 57554-120 is assigned by the FDA to the product Dermawound Wound Care Venous Stasis. It is commonly known by its generic name, benzocaine hydrochloride. This pharmaceutical product is labeled by Progressive Doctors, Llc and is currently categorized as listed product. The medication is a ointment administered via topical route. In terms of distribution, this product is available in a single package configuration. The associated package NDC(s) include: 57554-120-06. Beyond standard identification, this entry provides technical data including pharmacologic classes, UNII ingredient references, and RxNorm cross-referencing for healthcare systems.

What are the uses of this product?

•Gently clean around the affected area•Prior to application of DermaWound®, evaluate the wound or ulcer to insure no excessive bleeding is present. Never wipe out the ulcer.•Apply a moderate amount of DermaWound® directly to affected area.•Deeper or "tunneling" wounds may require packing and/or sides coated with additional DermaWound® and sterile gauze.•Apply additional sterile gauze to absorb exudates, if needed.•Change Dressing 2 or 3 times daily or as directed by a physician.•May require supervision of a health care professional in the management of chronic & acute wound care, pressure sores, diabetic ulcers, surgical wounds & indwelling catheters.

What are Active Ingredients of this product?

An active ingredient is the substance responsible for the medicinal effects of a product specified by the substance's molecular structure or if the molecular structure is not known, defined by an unambiguous definition that identifies the substance. Each active ingredient name is the preferred term of the UNII code submitted.
  • BENZOCAINE 1.27 g/100g - A surface anesthetic that acts by preventing transmission of impulses along NERVE FIBERS and at NERVE ENDINGS.

Which are the associated UNII Codes?

The UNII codes for the active ingredients in this product are:

Which are the Inactive Ingredients associated UNII Codes?

The inactive ingredients are all the component of a medicinal product OTHER than the active ingredient(s). The acronym "UNII" stands for “Unique Ingredient Identifier” and is used to identify each inactive ingredient present in a product. The UNII codes for the inactive ingredients in this product are:

What is the NDC to RxNorm Crosswalk for this product?

RxNorm is a normalized naming system for generic and branded drugs that assigns unique concept identifier(s) known as RxCUIs to NDC products.The NDC to RxNorm Crosswalk for this produdct indicates multiple concept unique identifiers (RXCUIs) are associated with this product:
  • RxCUI: 1552221 - benzocaine HCl 1.27 % Topical Ointment
  • RxCUI: 1552221 - benzocaine hydrochloride 0.0127 MG/MG Topical Ointment
  • RxCUI: 1552221 - benzocaine hydrochloride 1.27 % Topical Ointment
  • RxCUI: 1552226 - DermaWound Venous Stasis Formula 1.27 % Topical Ointment
  • RxCUI: 1552226 - benzocaine hydrochloride 0.0127 MG/MG Topical Ointment [Dermawound Benzocaine]

Which are the Pharmacologic Classes of this product?

A pharmacologic class is a group of drugs that share the same scientifically documented properties. The following is a list of the reported pharmacologic class(es) corresponding to the active ingredients of this product.

* Please review the full disclaimer at the bottom of this page.

Product & Regulatory Definitions
What is the Non-Proprietary Name? The non-proprietary name is sometimes called the generic name. The generic name usually includes the active ingredient(s) of the product.
What is the Substance Name? An active ingredient is the substance responsible for the medicinal effects of a product specified by the substance's molecular structure or if the molecular structure is not known, defined by an unambiguous definition that identifies the substance. Each active ingredient name is the preferred term of the UNII code submitted.
What kind of product is this? Indicates the type of product, such as Human Prescription Drug or Human Over the Counter Drug. This data element matches the “Document Type” field of the Structured Product Listing.
What are the Administration Routes? The translation of the route code submitted by the firm, indicating route of administration.
What is the Labeler Name? Name of Company corresponding to the labeler code segment of the Product NDC.
What is the FDA Application Number? This corresponds to the NDA, ANDA, or BLA number reported by the labeler for products which have the corresponding Marketing Category designated. If the designated Marketing Category is OTC Monograph Final or OTC Monograph Not Final, then the Application number will be the CFR citation corresponding to the appropriate Monograph (e.g. “part 341”). For unapproved drugs, this field will be null.
What is the Marketing Category? Product types are broken down into several potential Marketing Categories, such as NDA/ANDA/BLA, OTC Monograph, or Unapproved Drug. One and only one Marketing Category may be chosen for a product, not all marketing categories are available to all product types. Currently, only final marketed product categories are included. The complete list of codes and translations can be found at www.fda.gov/edrls under Structured Product Labeling Resources.
What is the Start Marketing Date? This is the date that the labeler indicates was the start of its marketing of the drug product.
What is the Listing Expiration Date? This is the date when the listing record will expire if not updated or certified by the product labeler.
What is the NDC Exclude Flag? This field indicates whether the product has been removed/excluded from the NDC Directory for failure to respond to FDA"s requests for correction to deficient or non-compliant submissions, or because the listing certification is expired, or because the listing data was inactivated by FDA, or because it was discontinued by the labeler. Possible values in this field are: "D", "E", "I", "N", "U".